{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:46:09Z","timestamp":1784328369894,"version":"3.55.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To compare the efficacy and safety of HU00701 (0.01% cyclosporin\n                      <jats:italic toggle=\"yes\">A<\/jats:italic>\n                      \u2009+\u20093% trehalose), HU007 (0.02% cyclosporin\n                      <jats:italic toggle=\"yes\">A<\/jats:italic>\n                      \u2009+\u20093% trehalose) (all w\/v), and placebo in patients with moderate to severe dry eye disease (\n                      <jats:sc>DED<\/jats:sc>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a multicenter, randomized, double-masked, parallel, placebo-controlled phase II study. In total, 114 patients were randomly assigned to the HU00701, HU007, placebo, or reference group. There was a 2-week run-in period before the 12-week intervention. Efficacy and safety were evaluated every 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The primary endpoint, change in corneal staining score from baseline to week 12, did not differ significantly among the control, HU00701, and HU007 groups in the full analysis. Of the secondary endpoints, only the tear film breakup time differed significantly at week 12 between the placebo and HU00701 groups. Twenty adverse events were reported by 15 patients, but the rate did not differ significantly among the 4 groups. The laboratory test, vital signs, and physical examination data showed no significant changes during the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      HU00701 and HU007 are safe, and HU007 effectively reduces the corneal staining score in patients with moderate-to-severe\n                      <jats:sc>DED<\/jats:sc>\n                      (NCT02917512).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0104","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T13:22:55Z","timestamp":1610716975000},"page":"4-11","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease"],"prefix":"10.1177","volume":"37","author":[{"given":"Jeongah","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Daejeon St. Mary's Hospital, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Rae","family":"Rho","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Daejeon St. Mary's Hospital, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Hyon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Young","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Chul","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chonnam National University, Chonnam National University Hospital, Gwangju, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choun-Ki","family":"Joo","sequence":"additional","affiliation":[{"name":"CK St. Mary's Eye Center, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.005"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.9.1264"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90171-9"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.02.002"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00192-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.11.1489"},{"key":"e_1_3_4_11_2","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole F.","year":"2001","unstructured":"Brignole F., , Pisella P.J., , De Saint Jean M., , Goldschild M., , Goguel A., , and Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest. Ophthalmol. Vis. Sci. 42:90\u201395, 2001.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S184412"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544030-00003"},{"key":"e_1_3_4_14_2","first-page":"577","article-title":"Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology","volume":"5","author":"Luyckx J.","year":"2011","unstructured":"Luyckx J., , and Baudouin C. Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clin. Ophthalmol. 5:577\u2013581, 2011.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/0471140864.ps0409s59"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101487200"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200310000-00008"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5986"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713688508999960"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ICL.0000140910.03095.FA"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.opx.0000171818.01353.8c"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000288"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.050"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.01.024"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.12.027"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308505"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-018-0820-7"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.026"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S226168"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2014.12.006"},{"key":"e_1_3_4_31_2","first-page":"631","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall K.","year":"2000","unstructured":"Sall K., , Stevenson O.D., , Mundorf T.K., , and Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 107:631\u2013639, 2000.","journal-title":"CsA Phase 3 Study Group. Ophthalmology"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1242\/jeb.01133"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-004-0085-8"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13342"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000836"},{"key":"e_1_3_4_36_2","first-page":"595","article-title":"A randomized crossover study comparing trehalose\/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome","volume":"11","author":"Pinto-Bonilla J.C.","year":"2015","unstructured":"Pinto-Bonilla J.C., , Del Olmo-Jimeno A., , Llovet-Osuna F., , and Hernandez-Galilea E. A randomized crossover study comparing trehalose\/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome. Ther. Clin. Risk. Manag. 11:595\u2013603, 2015.","journal-title":"Ther. Clin. Risk. Manag"},{"key":"e_1_3_4_37_2","first-page":"967","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial","volume":"107","author":"Stevenson D.","year":"2000","unstructured":"Stevenson D., , Tauber J., , and Reis B.L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 107:967\u2013974, 2000.","journal-title":"The Cyclosporin A Phase 2 Study Group. Ophthalmology"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S101627"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:17Z","timestamp":1777646657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1089\/jop.2020.0104"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0104","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}